Unicycive Therapeutics Resubmits NDA for Novel Phosphate Binder Targeting Hyperphosphatemia in Dialysis Patients
核心洞察
Unicycive Therapeutics has resubmitted its New Drug Application to the FDA for oxylanthanum carbonate, an investigational oral phosphate binder for treating hyperphosphatemia (搜索) in chronic kidney disease (搜索) patients on dialysis.
The resubmission follows resolution of manufacturing compliance issues by the company's third-party vendor, with the FDA expected to provide a new PDUFA date within 30 days.
The novel nanoparticle-based drug offers potential advantages over existing treatments by reducing pill burden for patients, addressing a significant adherence challenge in the over 450,000 U.S. patients requiring phosphate control medication annually.
Unicycive Therapeutics announced on December 29, 2025, that it has resubmitted its 505(b)(2) New Drug Application to the U.S. Food and Drug Administration for oxylanthanum carbonate (OLC), an investigational oral phosphate binder designed to treat hyperphosphatemia (搜索) in patients with chronic kidney disease (搜索) on dialysis. The biotechnology company expects to receive a new Prescription Drug User Fee Act target date within 30 days of the resubmission.
Manufacturing Compliance Resolution Enables Resubmission
The NDA resubmission follows significant progress by Unicycive's original third-party manufacturing vendor in resolving FDA-cited deficiencies and demonstrating inspection readiness. "Our original third-party manufacturing vendor has made significant progress toward regaining FDA compliance, allowing us to resubmit the OLC NDA as planned," said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive.
The company had previously addressed these manufacturing concerns during a Type A meeting with the FDA in September 2025, which focused on resolving the single deficiency identified in the Complete Response Letter received in June 2025. The deficiency was specifically related to the compliance status of the manufacturing vendor, and no additional issues were raised by the FDA during the meeting. Following the CRL, European Union regulatory authorities conducted an inspection of the manufacturing vendor and identified no deficiencies.
Novel Nanoparticle Technology Addresses Treatment Burden
Oxylanthanum carbonate leverages proprietary nanoparticle technology to deliver high phosphate binding potency while reducing the number and size of pills patients must take. This potential best-in-class profile may provide meaningful patient adherence benefits over currently available treatment options due to its lower pill burden requirement.
The drug candidate is being developed through the 505(b)(2) regulatory pathway, with the NDA submission package based on data from three clinical studies: a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study of OLC in CKD patients on dialysis. The submission also includes multiple preclinical studies and chemistry, manufacturing and controls data.
Addressing Significant Unmet Medical Need
Hyperphosphatemia (搜索) represents a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (搜索). Annually, over 450,000 individuals in the U.S. require medication to control their phosphate levels. Uncontrolled hyperphosphatemia is strongly associated with increased death and hospitalization for CKD patients on dialysis.
Current treatment approaches aim to lower serum phosphate levels through dietary phosphorus restriction and daily use of oral phosphate binding drugs with each meal. These medications facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream.
Strong Intellectual Property Protection
OLC is protected by a comprehensive global patent portfolio, including issued patents on composition of matter with exclusivity until 2031. The company has the potential for patent term extension until 2035, providing substantial market protection upon approval.
Financial Position and Timeline
Gupta emphasized the company's financial readiness for the regulatory process, stating, "With a cash runway into 2027, we are well-positioned to complete the regulatory approval process for OLC so we can prepare to bring this important treatment option to dialysis patients with hyperphosphatemia (搜索) as soon as possible."
Under Prescription Drug User Fee Act target guidelines for NDA resubmissions, the FDA typically acknowledges acceptance for review within 30 days of submission and completes the submission review within 6 months, setting the stage for a potential approval decision in the first half of 2026.